Life Sciences Blog

GlaxoSmithKline signs deal with MD Anderson

Posted on December 7th, by Michael Shapiro-Barr

GlaxoSmithKline has signed a collaboration agreement with MD Anderson Cancer Center to develop new cancer fighting drugs.  In the agreement, GlaxoSmithKline will provide MD Anderson with an undisclosed upfront payment and research funding.  MD Anderson could earn $335 million plus royalties if this agreement leads to approved medicines.

Read More



Comments are closed.

Recent Posts

Enter your email address to subscribe to this blog and receive notifications of new posts by email.


From the Blog

Where to Spend Your Healthcare Investment Dollars

In a blog entry written over the summer, I expressed the view that the next 5-10 years will present tremendous transactional opportunities in the life...

Second Circuit Rejects Government’s Off-Label Enforcement Approach

Last week’s decision in the off-label promotion case, United States v. Caronia, No. 09-5006-cr (2d Cir. Dec. 3, 2012), is an important blow to...

Massachusetts Refines Its Sunshine Law; Final Federal Sunshine Regulations Moving Ahead

The relationship between health care providers and drug and device manufacturers has been a focus of lawmakers at both the federal and state level. ...

Subscribe by Email for New Blog Posts